

PATENT Docket No. 249.00070101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Dominic COSGROVE)	Group Art Unit:	1644
Serial No.:	10/698,121)	Examiner:	Maher M. Haddad
Confirmation	-)		
Filed:	October 31, 2003)		
For:	INDUCIBLE LIGAND FOR) α1β1 Π	NTEGRIN AND I	USES

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop AF Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of candor and good faith that is to be demonstrated before the United States Patent and Trademark Office (USPTO), enclosed are copies of four documents cited in a Supplementary Partial European Search Report for related European Patent Application No. 03781670.9-1222 which are not already of record in the present matter. Enclosed for the Examiner's information is a copy of the search report with the documents. Pursuant to MPEP § 609, the information cited in the present Information Disclosure Statement shall not be construed to be an admission that the information is, or is considered to be, material to patentability. Consideration of each of the documents listed on the attached 1449 form is respectfully requested. Pursuant to the provisions of MPEP §609, Applicant further requests that a copy of the 1449 form, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Since this Supplemental Information Disclosure Statement is submitted after receipt of a Final Office Action in the above-identified patent application, Applicant hereby authorizes a charge of \$180 to Deposit Account No. 13-4895 to cover the fee required under 37 CFR §§1.97(d) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 13-4895.

Supplemental Information Disclosure Statement

Applicant(s): Dominic COSGROVE

Serial No.: 10/698,121 Confirmation No.: 8958 Filed: October 31, 2003

For: INDUCIBLE LIGAND FOR α1β1 INTEGRIN AND USES

CERTIFICATION

Under 1.97(e)(1), the undersigned attorney hereby certifies that each item of information contained in this Supplemental Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

When the Examiner takes up the present application, consideration of these documents is respectfully requested. The Examiner is invited to contact Applicant's Representatives at the below-listed telephone number, if they can be of any assistance during prosecution of the present application.

CERTIFICATE UNDER 37 C.F.R. 1.10:

The undersigned hereby certifies that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date indicated below and is addressed to Mail Stop AF, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature: Deb Schurmann

"Express Mail" mailing label number:

EV 201877815 US

Date of Deposit: January 16, 2007

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Telephone (612)305-1220

Facsimile (612)305-1228

Customer Number 26813

January 16,2007

Nancy A. Johnson Reg. No. 47,266

Direct Dial (612) 305-4723

INFORMATION
DISCLOSURE
STATEMENT

Atty. Docket No.: 249.00070101	Serial No.: 10/698,121		
Applicant(s): Dominic COSGROVE	Confirmation No.: 8958		
Application Filing Date: October 31, 2003	Group: 1644		
Information Disclosure Statement mailed:	January 16, 2007		

JAN 1 6 2007

U.S. PATENT DOCUMENTS

Examina	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	None					

FOREIGN PATENT DOCUMENTS

Examiner	Document Number	Date	Country	Class	Subclass	Trans	lation
Initial						Yes	No
	None						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	Dennis et al., "Collagen XIII is induced on endothelial cells and may mediate VLA1-dependent monocyte efflux in chronic renal fibrosis" Experimental Biology 2004 Conference, Washington, DC, April 17-21, 2004; 1 pg.
	X	Gullberg et al., "Collagen-binding I domain integrins - what do they do?" <i>Progr. Histochem. Cytochem</i> , 2002; 37(1):title page, author acknowledgement page, table of contents, list of abbreviations, abstract and pages 10-54.
	X	Pihlajaniemi et al., "The α1 chain of type XIII collagen consists of three collagenous and four noncollagenous domains, and its primary transcript undergoes complex alternative splicing" <i>Journal of Biological Chemistry</i> , 1990 Oct. 5; 265(28):16922-16928.
	X	Tu et al., "The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparin" <i>Journal of Biological Chemistry</i> , 2002 June 21; 277(25):23092-23099.

EXAMINER	Date Considered

^{*}Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.